Revolution Medicines Inc. Common Stock (RVMD)
Stock · NASDAQ · Health Care
$207.88as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support Confirmation35.0%
High Beta24.1%
Support level
$96.05
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to s…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 883
- Website
- www.revmed.com/
Fundamentals
- 1-day range
- $205.82$220.81
- Market cap
- $38.79B
- P/E (trailing)
- —
- P/E (forward)
- -33.55
- EPS (trailing)
- $-4.80
- Dividend yield
- —
- Beta
- 1.42
- Avg. volume
- 2.54M
52-week range
$35.64$224.31
Next earnings: November 4, 2026 · EPS estimate $-2.46After Closeconfirmed
How Revolution Medicines Inc. Common Stock Makes Money
Where the revenue actually goes — FY2022 annual results
Source: 10-K filed Feb 27, 2023 · via SEC EDGAR / Finnhub
Forecasts
21 analyst ratings
Buy 93%
Hold 7%
Sell 0%
1-year price forecast
High
$320
+53.9%
Median
$239
+15.0%
Low
$179
-13.9%
Revolution Medicines Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- RVMDRevolution Medicines Inc. Common Stock$207.89▼ 6.00%Market cap $38.79BP/E —$35.64$224.31
- ARGXargenx SE American Depositary Shares$1,025▼ 3.22%Market cap $51.56BP/E 22.19$568.4$913
- BNTXBioNTech SE American Depositary Share$102.04▼ 8.40%Market cap $23.18BP/E —$79.52$124
- MRNAModerna Inc. Common Stock$137.93▼ 3.39%Market cap $21.88BP/E —$22.28$176.66
- HALOHalozyme Therapeutics Inc. Common Stock$105.33▼ 1.49%Market cap $9.76BP/E 27.63$61.23$109.66
- QGENQiagen N.V. Common Shares$43.12▼ 1.43%Market cap $8.72BP/E 22.14$32.53$57.82
- KYMRKymera Therapeutics Inc. Common Stock$118.08▼ 1.79%Market cap $8.25BP/E —$39.84$130.05
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RVMD Revolution Medicines Inc. Common Stock | $38.79B | — | $207.89 | ▼ 6.00% | $35.64$224.31 |
| ARGX argenx SE American Depositary Shares | $51.56B | 22.19 | $1,025 | ▼ 3.22% | $568.4$913 |
| BNTX BioNTech SE American Depositary Share | $23.18B | — | $102.04 | ▼ 8.40% | $79.52$124 |
| MRNA Moderna Inc. Common Stock | $21.88B | — | $137.93 | ▼ 3.39% | $22.28$176.66 |
| HALO Halozyme Therapeutics Inc. Common Stock | $9.76B | 27.63 | $105.33 | ▼ 1.49% | $61.23$109.66 |
| QGEN Qiagen N.V. Common Shares | $8.72B | 22.14 | $43.12 | ▼ 1.43% | $32.53$57.82 |
| KYMR Kymera Therapeutics Inc. Common Stock | $8.25B | — | $118.08 | ▼ 1.79% | $39.84$130.05 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Top 3 Health Care Stocks That May Keep You Up At Night In Q3benzinga · 8/27/2026
- Bernstein Maintains Market Perform on Revolution Medicines, Raises Price Target to $179Benzinga · 8/21/2026
- Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $231Benzinga · 8/11/2026
- BeOne Medicines And Revolution Medicines Form Clinical Collaboration To Evaluate Drug Combinations Using Select Clinical-Stage Oncology Assets From BeOne With Any Of Revolution’s Four Clinical RAS(ON) InhibitorsBenzinga · 8/10/2026
- Here’s How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 YearsBenzinga · 8/7/2026
- High Risk, High Reward: Inside The Revolution Medicines Bull CaseSeekingAlpha · 8/7/2026
- RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $203Benzinga · 8/6/2026
- Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $201Benzinga · 8/6/2026
- Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $230Benzinga · 8/6/2026
Insider Activity
Insider Actions →Acquired
26.1K
Disposed
25.3K
- Sushil Patel · June 29, 2026 · Option Exercise3.0K @ $37.54
- Sushil Patel · June 29, 2026 · Sale881 @ $192.61
- Sushil Patel · June 29, 2026 · Sale541 @ $191.87
- Sushil Patel · June 29, 2026 · Sale600 @ $190.55
- Sushil Patel · June 29, 2026 · Sale100 @ $188.57
- Sushil Patel · June 29, 2026 · Sale300 @ $183.17
- Sushil Patel · June 29, 2026 · Sale858 @ $186.92
- Sushil Patel · June 29, 2026 · Sale1.1K @ $185.9
- Sushil Patel · June 29, 2026 · Sale900 @ $184.59
- Jack Anders · June 24, 2026 · Option Exercise20.0K @ $18.56
- Jack Anders · June 24, 2026 · Sale300 @ $170.32
- Jack Anders · June 24, 2026 · Sale5.7K @ $169.24
- Jack Anders · June 24, 2026 · Sale9.5K @ $168.2
- Jack Anders · June 24, 2026 · Sale4.6K @ $167.35
- Lorence H. Kim · June 18, 2026 · Grant3.1K
Institutional Ownership
March 31, 2026
- Total shares held
- 197.06M
- Total value held
- $18.44B
- Institutional holders
- 507
Top holders this quarter
- Unknown13.60M
- Unknown11.21M
- Unknown9.77M
- Unknown9.56M
- Unknown8.46M
- Unknown8.36M
- Unknown7.60M
- Unknown6.66M
- Unknown6.03M
- Unknown5.48M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedSynthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
August 30, 2026
RVMD Gains After Landmark FDA Approval of RASONQUE for Pancreatic Cancer. Revolution Medicines received FDA approval for RASONQUE, a treatment for metastatic pancreatic cancer, marking a significant milestone for the company and for therapies targeting RAS-driven cancers. The approval drew attention across the oncology sector, lifting shares of related firms and drawing coverage from analysts. UBS and Guggenheim both raised their price targets on RVMD following the news, with the average analyst target now standing at $214.71. Shares were trading near the upper end of their 52-week range of $35.64 to $224.31 as the news was digested.